@LennMcD @ACRheumDC Do policies affect medication access, costs, reimbursements, telehealth, or your life as a rheumatology provider or patients? Contact - quick and easy! https://t.co/TvMlXiIZQR @RheumNow #ACR24 https://t.co/plnUtl7Kml https://t.co/lFGx7hzlKy

• Contact Federal Policymakers
• https://x.com/ericdeinmd/status/1858156009358831975/photo/1
• https://twitter.com/ericdeinmd/status/1857850440357953789

@LennMcD @ACRheumDC Current congress (118th) - very tight margins, paralyzed by the ‘24 elections. Now in lame duck Many ACR policies made into bills - PA, step rx, copay accumulator, workforce, loan repayment, incr Rx transparency Needs to be passed into law @RheumNow #ACR24 https://t.co/1elEUiUAmh

• https://x.com/ericdeinmd/status/1858153751158132967/photo/1

Managing DMARDs in pregnancy. Curbside consults by Lisa Sammaritano @RheumNow #ACR24 https://t.co/FQrLNz4yCz

• https://x.com/synovialjoints/status/1857881212393533685/photo/1

Phase 2 DBRCT of daxdilimab, an immunoglobulin-like transcript 7 to target plasmacytoid dendritic cells No difference in primary outcome... but kiiiinda looks like something there? I dislike Phase 2's; should go straight to Phase 3 if able #ACR24 @rheumnow Abstr#1542 https://t.co/osDWDskfnA

• https://x.com/EBRheum/status/1858028042188444095/photo/1
• https://x.com/EBRheum/status/1858028042188444095/photo/1

@KDAO2011 help me out here; what is the point of analyses like this? NO difference in PROs comparing voclo vs plbo... ...but if you split by responder status its different Prescribing the drug doesn't help PROs, but when it works it works? 🤔 #ACR @RheumNow Abstr#1538 https://t.co/339drHwUuK

• https://x.com/EBRheum/status/1858034836423766179/photo/1

This is very true. We showed a number of years ago that patients with gout have increased platelet activation at baseline, which then dramatically increases during flare. Treating gout properly may ameliorate this. #ACR24 @RheumNow https://t.co/VL8fy3ezjx https://t.co/9XdrG1NG9c

• Increased platelet reactivity as measured by plasma glycoprotein VI in gout
• https://twitter.com/RoxOsler/status/1857776584112890292

Factors associated w/ secukinumab response in PsA? Analysis of 2.7k pt in EuroSpA Associated w/ favorable response ❗️elevated CRP >10 mg/L ❗️fewer prev tx Associated w/ lower response: ❗️smoking ❗️higher patient global score / HAQ @RheumNow #ACR24 Abstr 2325

New data to guide role of long-term, low dose GC in GPA Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily Fewer relapses on 5mg pred but w/qualifications: 👉 most flares = minor 👉 no difference in flares if RTX on board @RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM

• https://x.com/Dr_Brian_MD/status/1857912184010928404/photo/1
• https://x.com/Dr_Brian_MD/status/1857912184010928404/photo/1

Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx

• Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchici…
• https://x.com/RichardPAConway/status/1857896424786243864/photo/1

🤵‍♂️Results from BACHELOR ➡️34 PMR pts ➡️18 BARI, 16 PBO ➡️Primary endpoint: CRP PMR-AS≤10 w/o oral GC rescue from W0 to 12 78% BARI pts reached primary endpoint vs 13% PBO No new safety signals BARI 4mg 12W, then 2mg 12W➡️36W low disease activity in PMR Ab0858 #ACR24 @RheumNow